Under the leadership of Chief Science Officer
The Company is scheduled to begin production and analytical testing of MDMA this October in its recently completed EU-GMP pharmaceutical manufacturing facility.
Optimi CEO,
“From lab to market, Optimi has taken every step necessary to build its competitive position as a global leader in the manufacturing of EU-GMP compliant MDMA in
He further added, “On compliance, quality, and scale, we have consistently demonstrated our plan to lead the industry in API synthesis and formulation, which gives our science and operations team the confidence to develop saleable psychedelic products that are supported by rigorous in-house Standard Operating Procedures (SOP),” said Ciprick.
The terms of the amendment took effect as of
Since applying for the amendment in June, the Company has met with industry stakeholders, drug developers, and clinical trial researchers interested in exploring Optimi’s production capabilities, reaffirming the Company’s decision to proceed with this phase of its commercialization strategy.
Regulatory Opportunity
In
With 130 MDMA clinical trials currently listed between
“The regulatory landscape in the
On
In addition to MDMA, the Company now has
N,N-Dimethyltryptamine ("DMT");
3,4,5-trimethoxyphenethylamine ("Mescaline");
2-(2-chlorophenyl)-2- (methylamino)cyclohexanone ("Ketamine");
Lysergic Acid Diethylamide ("LSD");
1-(1-phenylcyclohexyl)piperidine ("Phencyclidine");
4-Hydroxybutanoic Acid ("GHB");
4,9–dihydro–7–methoxy–1–methyl–3H–pyrido(3,4–b)indole ("Harmaline");
4,9–dihydro–1–methyl–3H–pyrido(3,4–b)indol–7–ol ("Harmalol");
Salvia Divinorum, Salvinorin A; and,
4-Bromo-2,5-Dimethoxybenzeneethanamine ("2C-B").
Authorized parties interested in purchasing Optimi psilocybin and functional mushroom products, MDMA, or other additional psychedelics are invited to contact sales@optimihealth.ca where a member of the sales team will respond within 24 hours.
ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)
FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:
Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
www.optimihealth.ca
FORWARD‐LOOKING STATEMENTS
This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐looking statements pertaining to activities proposed to be conducted under the Company’s dealer’s licence and associated business related to Psilocybin, Psilocin, other psychedelic substances, and Optimi’s plans, focus and objectives.
Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual information Form dated
Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/7026a95a-2bf1-4371-bc9d-584e4016ebc3
https://www.globenewswire.com/NewsRoom/AttachmentNg/c6c08403-50b6-47b8-aec0-c676b7c52dcd
https://www.globenewswire.com/NewsRoom/AttachmentNg/c2bf650a-5ad3-48b0-a6fe-c2b0828f501a
Optimi Health
Optimi Health Analytical Laboratory in Princeton, BC .
Optimi Health
Inside of Optimi Health analytical laboratory.
Optimi Health
Optimi Health analytical equipment.
2022 GlobeNewswire, Inc., source